6265 related articles for article (PubMed ID: 18047501)
1. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
4. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
Mathew NT; Kailasam J; Meadors L
Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
Blumenfeld AM; Schim JD; Chippendale TJ
Headache; 2008 Feb; 48(2):210-20. PubMed ID: 18047502
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
Saper JR; Mathew NT; Loder EW; DeGryse R; VanDenburgh AM;
Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321
[TBL] [Abstract][Full Text] [Related]
7. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches.
Relja M; Poole AC; Schoenen J; Pascual J; Lei X; Thompson C;
Cephalalgia; 2007 Jun; 27(6):492-503. PubMed ID: 17428299
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S
Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
[TBL] [Abstract][Full Text] [Related]
9. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
10. Duration of migraine is a predictor for response to botulinum toxin type A.
Eross EJ; Gladstone JP; Lewis S; Rogers R; Dodick DW
Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type A in prophylactic treatment of migraine.
Anand KS; Prasad A; Singh MM; Sharma S; Bala K
Am J Ther; 2006; 13(3):183-7. PubMed ID: 16772757
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study.
Silberstein SD; Göbel H; Jensen R; Elkind AH; Degryse R; Walcott JM; Turkel C
Cephalalgia; 2006 Jul; 26(7):790-800. PubMed ID: 16776693
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial.
Vo AH; Satori R; Jabbari B; Green J; Killgore WD; Labutta R; Campbell WW
Aviat Space Environ Med; 2007 May; 78(5 Suppl):B113-8. PubMed ID: 17547312
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
[TBL] [Abstract][Full Text] [Related]
15. Headache prophylaxis with BoNTA: patient characteristics.
Silberstein SD; Marmura MJ; Shaw J; Yu S
Headache; 2010 Jan; 50(1):63-70. PubMed ID: 19549156
[TBL] [Abstract][Full Text] [Related]
16. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
[TBL] [Abstract][Full Text] [Related]
17. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse.
Freitag FG; Diamond S; Diamond M; Urban G
Headache; 2008 Feb; 48(2):201-9. PubMed ID: 18042229
[TBL] [Abstract][Full Text] [Related]
18. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial.
Sahai A; Dowson C; Khan MS; Dasgupta P
BJU Int; 2009 Jun; 103(11):1509-15. PubMed ID: 19389019
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study.
Naumann M; Lowe NJ; Kumar CR; Hamm H;
Arch Dermatol; 2003 Jun; 139(6):731-6. PubMed ID: 12810503
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.
Evers S; Vollmer-Haase J; Schwaag S; Rahmann A; Husstedt IW; Frese A
Cephalalgia; 2004 Oct; 24(10):838-43. PubMed ID: 15377314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
